News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase II
Onxeo: Positive Phase 2 Preliminary Results Of Validive® For The Prevention Of Severe Oral Mucositis In Head And Neck Cancer Patients 10/31/2014
BioLineRx Ltd. Reports Publication In Peer Review Journal Of Results From Previous Phase 1/2 Trial For BCM (BL-1040), A Novel Medical Device For Prevention Of Cardiac Remodeling Following Acute Myocardial Infarction 10/31/2014
Bristol-Myers Squibb Company (BMY)'s Opdivo Wows In Phase 2 Lung Cancer Study 10/30/2014
BIND Therapeutics (BIND) Announces Availability Of Abstract With Preliminary Data From Phase 2 Study Of BIND-014 In Non-Small Cell Lung Cancer 10/30/2014
Baxter International, Inc. (BAX)’s Investigational 20% Subcutaneous Immunoglobulin Treatment Meets Efficacy And Tolerability Endpoints In Phase 2/3 Study 10/30/2014
Kiadis Pharma's Lead Product ATIR™ Granted Orphan Drug Designation By European Medicines Agency For The Treatment Of Acute Myeloid Leukemia 10/30/2014
AnaMar AB Reports Top-Line Results From Exploratory Phase 2a Study Of AMAP102 And Provides Corporate Update 10/30/2014
Neurocrine Biosciences, Inc. (NBIX) Receives Breakthrough Therapy Designation For NBI-98854 In Tardive Dyskinesia 10/30/2014
Ultragenyx Pharmaceuticals (RARE) Granted EU Orphan Drug Designation For KRN23 For The Treatment Of X-Linked Hypophosphatemia 10/30/2014
GW Pharmaceuticals Commences Phase 2/3 Clinical Trial Of Epidiolex® As A Potential Treatment For Epilepsy In Dravet Syndrome 10/30/2014
Recro Pharma (REPH) Announces Dosing Of First Patient In Phase 2 REC-14-013 Clinical Trial Of Dex-IN For Treatment Of Acute Pain On Day 1 Following Surgery 10/30/2014
Immunomedics, Inc. (IMMU) Provides Update On Phase 2 Study Of Isactuzumab Govitecan In Patients With Diverse Metastatic Solid Cancers 10/30/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.)'s VC-01™ Investigational Stem Cell-Derived Islet Replacement Therapy Successfully Implanted Into First Patient 10/29/2014
Cara Therapeutics, Inc. (CARA) Touts Positive Data From New Opiod Pain Drug Trial 10/29/2014
Synta Pharmaceuticals (SNTA) Announces Initiation Of I-SPY 2 TRIAL Of Ganetespib In Breast Cancer 10/29/2014
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/28/2014
New Clinical Trial Data: The Scripps Research Institute MS Drug Candidate Also Shows Promise For Ulcerative Colitis 10/28/2014
TxCell Achieves Positive Results For Col-Treg In A Model Of Autoimmune Uveitis 10/28/2014
Receptos (RCPT) Soars As Bowel Disorder Drug Meets Phase 2 Goals 10/28/2014
Araim Pharmaeuticals Given FDA Fast Track Designation To ARA 290 For The Treatment Of Sarcoidosis-Associated Small Fiber Neuropathy 10/28/2014
Moberg Pharma AB (Formerly known as Moberg Derma): First Patient Included In Phase 2 Study Of BUPI, A Novel Topical Formulation For Treatment Of Oral Pain 10/28/2014
Apogenix- Positive Results From APG101 Phase 2 Clinical Trial Published In Clinical Cancer Research 10/28/2014
Akebia Therapeutics, Inc. (AKBA)'s Lead Drug AKB-6548 Succeeds In Mid-Stage Trial 10/27/2014
Clementia Announces Open-Label Phase 2 Extension Study Of Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva 10/27/2014
Metanome, Inc. Selected As Metagenics Inc. Provider For Seres Health Clinical Trial 10/27/2014
Sunovion Pharmaceuticals Inc. Announces Dose Ranging Data From Phase 2 Study Of SUN-101 (Glycopyrrolate) Inhalation Solution For Treatment Of Patients With Moderate-To-Severe Chronic Obstructive Pulmonary Disease (COPD) 10/27/2014
Ultragenyx Pharmaceuticals (RARE) Granted Orphan Drug Designation For Triheptanoin For The Treatment Of Glucose Transporter Type-1 Deficiency Syndrome 10/27/2014
Generex Biotechnology Corporation (GNBT) Announces Presentations Correlating Immunological Response With Reduced Recurrence In Phase 2 Study Of AE37 Breast Cancer Vaccine In Patients At The American College of Surgeons 10/27/2014
Burzynski Research Institute Announces FDA Permission To Launch A New Clinical Trial In Diffuse Intrinsic Brainstem Glioma 10/27/2014
PTC Therapeutics, Inc. (PTCT) Release: Translarna™ Phase 2b Data Published In Muscle & Nerve 10/27/2014
Heat Biologics Commences Patient Dosing Of Phase 2 Clinical Study Of Vesigenurtacel-L For The Treatment Of Bladder Cancer 10/27/2014
Rhythm Presents Positive Phase 2 Study Results For Relamorelin For Chronic Constipation 10/24/2014
ALS ACT, The ALS Association, And The Northeast ALS Consortium Issue Request For Proposals For Phase 2 Clinical Development Of Novel, High-Potential Treatments For ALS 10/24/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1102 For MS – FDA Response To Phase 2b Study Plans 10/24/2014
Clovis Oncology (CLVS) Announces First Patient Enrolled In Lucitanib Phase 2 Study In Squamous Non-small Cell Lung Cancer 10/24/2014
Verastem, Inc. (VSTM) Presents New Data On Mesothelioma Programs At The 12th International Mesothelioma Interest Group Meeting 10/24/2014
Synageva BioPharma (GEVA) Presents Sebelipase Alfa Data At The NASPGHAN Meeting 10/24/2014
Ablynx (ABLYF)'s Ant-Il-6R Nanobody Partnered With AbbVie (ABBV) Demonstrates A Bioavailability Of More Than 80% After Subcutaneous Injection 10/23/2014
Cellceutix (CTIX) Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable To 7-Days Of Daptomycin 10/23/2014
Islet Sciences And BHV Announce Publication Of Two Phase 2b Clinical Studies Of Remogliflozin Etabonate For Treating Type 2 Diabetes 10/23/2014
NeuralStem Inc. Alzheimer's Disease Animal Data Presented At The Congress Of Neurological Surgeons Annual Meeting 10/23/2014
SAGE Therapeutics Initiates Exploratory Study Of SAGE-547 In Essential Tremor 10/23/2014
MediciNova, Inc. Announces FDA Granted Orphan Drug Designation To MN-001 (Tipelukast) For Idiopathic Pulmonary Fibrosis (IPF) 10/23/2014
Regulus Therapeutics, Inc. (RGLS) Gets Seat At Hepatitis C Table With Impressive Phase 1 Results 10/22/2014
GW Pharmaceuticals Announces Epidiolex® Receives Orphan Designation From European Medicines Agency For The Treatment Of Dravet Syndrome 10/22/2014
Immunomedics, Inc. (IMMU) To Present Updated Clinical Results With Solid-Tumor Antibody-Drug Conjugates At Upcoming Conferences 10/22/2014
Nuvo Research Inc. (NRI.TO) Completes WF10™ U.S. Market Study For Treatment Of Refractory Allergies 10/22/2014
Oramed Pharmaceuticals Inc. (ORMP) Reports Positive Top-Line Data From U.S. Phase 2a Trial With Oral Insulin In Type 1 Diabetes 10/22/2014
Hatchtech Announces Successful Results From Phase 2 Ovicidal Study 10/21/2014
Synergy Pharmaceuticals Presents Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation 10/21/2014
Generex Biotechnology Corporation (GNBT) Announces Publication Of Ebola Vaccine White Paper By Antigen Express, Inc. (GNBT) 10/21/2014
TWi Biotechnology Receives Orphan Drug Designation For Its Lead Drug Candidate AC-201 In United States 10/21/2014
Maxwell Biotech Portfolio Company Hepatera Announces Proof-Of-Concept Clinical Results With Myrcludex B, A Novel Entry Inhibitor For Treatment Of Chronic Hepatitis B And Delta 10/21/2014
Genervon Announces ALS And PD Phase 2a Trial Results 10/20/2014
Milo Biotechnology's Follistatin Gene Therapy Increases Function In Becker Muscular Dystrophy Patients 10/20/2014
Norgine Release: Positive Results From Phase 2 Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 10/20/2014
Immunomedics, Inc. (IMMU) Announces European Orphan Drug Designation For Isactuzumab Govitecan For Pancreatic Cancer Treatment 10/20/2014
CytRx Corporation (CYTR) Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society 10/20/2014
CytRx Corporation (CYTR) To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting 10/17/2014
Chimerix, Inc. (CMRX) Provides Update On Research and Development Progress; FDA OKs Brincidofovir In Phase 2 For Ebola Virus Disease 10/16/2014
Deltanoid Pharmaceuticals, Inc.'s DP001 (2MD) Pharmaceutical Demonstrated Safe And Effective In Kidney Failure Patients On Dialysis 10/16/2014
TherapeuticsMD, Inc.  (TXMD) Announces Oral Presentation Of Positive Phase 2 And Bioavailability Data On TX-004HR (VagiCaptm) 10/16/2014
Allegro Ophthalmics LLC Begins Phase 2 Clinical Trial Of Luminate® (ALG-1001) For The Treatment Of Diabetic Macular Edema 10/16/2014
Infinity Pharmaceuticals Inc. (INFI) Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma 10/16/2014
Ironwood Pharmaceuticals (IRWD) Announces Initiation Of Phase 2 Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation 10/16/2014
Amarantus BioSciences, Inc. Applies To FDA For MANF Orphan Drug Designation In Retinitis Pigmentosa 10/16/2014
Nanobiotix Receives First Approval To Start Phase 2/3 Registration Trial In Soft Tissue Sarcoma In Europe 10/16/2014
ContraVir Pharmaceuticals Selects Pharmaceutical Product Development To Manage Phase 2b Study Of Lead Antiviral FV-100 For Treating Shingles 10/16/2014
Tekmira (TKMR)'s Partner Reports Positive Clinical Data For LNP-Enabled Patisiran 10/15/2014
Cannabis Biopharma GW Pharmaceuticals Sees Disappointing Data For Colitis Drug 10/15/2014
Clearside Biomedical Announces Ongoing Results In Phase 1/2 Clinical Trial In Patients With Non-infectious Uveitis 10/15/2014
Sorrento Therapeutics, Inc. Release: Initial Pharmacokinetic Data From TRIBECA Study Support Potential For Bioequivalence Between Cynviloq And Albumin-Bound Paclitaxel 10/15/2014
Ohr Pharmaceutical (OHRP) Announces Successful End Of Phase 2 Meeting With The FDA On Squalamine Eye Drops (OHR-102) In Wet AMD 10/14/2014
Advaxis, Inc.'s Lm-LLO Immunotherapy Data To Be Presented In Three Posters At The Society For Immunotherapy Of Cancer 29th Annual Meeting 10/14/2014
EU-Funded Consortium Led By immatics biotechnologies GmbH And BioNTech To Advance A Novel Class Of Fully Personalized Therapeutic Cancer Vaccines Into Clinical Trials For Brain Cancer 10/14/2014
Scancell Release: AGM Research And Development Update Highlights Progress In Both SCIB1 Clinical Trial And Moditope® Platform 10/14/2014
Novavax, Inc. (NVAX) Initiates Phase 2 Clinical Trial Of RSV Vaccine In Elderly Subjects 10/14/2014
Intra-Cellular Therapies, Inc.'s Dementia Drug Meets Phase 1/2 Goals 10/13/2014
Lipocine Inc. (LPCN) Announces Positive Top-Line Results In Phase 2a Study Of LPCN 1111 10/13/2014
AVANIR Pharmaceuticals (AVNR) Announces Presentation Of AVP-923 Phase 2 Results In Agitation In Patients With Alzheimer's Disease At The American Neurological Association Meeting 10/13/2014
Alnylam Pharmaceuticals (ALNY) Reports Six-Month Clinical Data From Patisiran Phase 2 Open-Label Extension (OLE) Study In Patients With Familial Amyloidotic Polyneuropathy (FAP) 10/13/2014
Alios BioPharma Presented Positive Results Of Its Anti-RSV Nucleoside Analog AL-8176 In A Phase 2 Challenge Study In Adults Infected With Respiratory Syncytial Virus (RSV) At IDWeek 10/13/2014
Cellceutix (CTIX) Investigational New Drug (IND) Application Becomes Effective, Selects First Site For Phase 2 Clinical Trial Of New Treatment For Oral Mucositis 10/13/2014
CytoDyn Announces Investment Community Call To Discuss Results From Its Treatment Substitution Clinical Trial In Patients With HIV 10/13/2014
Tobira Therapeutics Inc. Doses First Patient In CENTAUR, A Phase 2b Study Of Cenicriviroc In Patients With Non-Alcoholic Steatohepatitis 10/13/2014
Amgen (AMGN)'s Leukemia Drug Blinatumomab Gets FDA Priority Review 10/10/2014
Biotron Limited (BIT:AU) Release: BIT225 Trial Results Show Effective Cure Of Hepatitis C 10/10/2014
Medivir AB (MVRBF): Phase 2 IMPACT Study Initiated To Evaluate Simeprevir In Combination With Sofosbuvir And Daclatasvir To Treat Genotype 1 And 4 Hepatitis C Patients 10/10/2014
MediciNova, Inc. Receives Feedback From FDA Regarding Study Protocol For Phase 2 Trial Of MN-001 (Tipelukast) In NASH 10/9/2014
Chimerix, Inc. (CMRX) Says Brincidofovir Improved Survival In Study Spurred By Boy 10/9/2014
Horizon Pharma plc.  (HZNP) Announces Presentation Of ACTIMMUNE(R) Phase 2 Data In Friedreich's Ataxia 10/9/2014
Bone Therapeutics Extends ALLOB® Phase I/IIa Trial To Germany 10/9/2014
Study Shows Rebiotix Microbiota-based Drug Candidate Targeted at Recurrent C. difficile Infection is Highly Effective 10/9/2014
Halozyme Therapeutics, Inc. (HALO) Announces Podium Presentation On PEGPH20 At The New York Academy of Sciences 10/9/2014
DelMar Pharmaceuticals Release: VAL-083 Demonstrates Promise As A Potential Treatment For Non-Small Cell Lung Cancer 10/9/2014
Galapagos NV (GLPG.BR) Presents Novel Cystic Fibrosis Combination Therapy At NACFC 10/9/2014
Rockwell Medical (RMTI) Announces FDA Advisory Committee Review Of Triferic For The Treatment Of Iron Replacement And Maintenance Of Hemoglobin In Hemodialysis Patients 10/9/2014
GenSpera Announces Completion Of Patient Enrollment In The Phase 2 Clinical Trial Of Mipsagargin In Liver Cancer Patients 10/9/2014
Amarantus BioSciences, Inc. Announces Positive LP-002 Data For Alzheimer's Blood Diagnostic Lympro Test® 10/9/2014
BrainStorm Cell Therapeutics Inc. Nabs FDA Fast-Track Status For ALS Stem Cell Therapy 10/8/2014
Merck & Co. (MRK) To Present New Data From Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) At The 65th American Association for Study of Liver Diseases Annual Meeting 10/8/2014
Arrowhead Research Corporation (ARWR) To Present ARC-520 Phase 2a Data In Late-Breaking Session At American Association for Study of Liver Diseases Liver Meeting® 2014 10/8/2014
Trevena, Inc. (TRVN) Announces Early Completion Of Enrollment Of Phase 2a/B Study Of TRV130 In Postoperative Pain 10/8/2014
AVANIR Pharmaceuticals (AVNR) Announces Data Presentations At The American Neurological Association's (ANA) 2014 Annual Meeting Including Results From The Phase 2 Trial For Treatment Of Agitation In Patients With Alzheimer's Disease 10/8/2014
Ruthigen Initiates Phase 1/2 Clinical Trial Of RUT58-60 10/8/2014
Pfizer (PFE) To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent Rlp2086, Co-Administered With A Licensed Human Papillomavirus Vaccine 10/8/2014
Synergy Pharmaceuticals To Present Additional Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation At American College of Gastroenterology 2014 Annual Scientific Meeting 10/7/2014
Holaira Announces First Patient Treatment In Randomized Study Of Targeted Lung Denervation For COPD 10/7/2014
Medgenics, Inc. To Present Initial Clinical Data From MDGN-201 Study At European Society Of Gene And Cell Therapy Congress 10/7/2014
RXi Pharmaceuticals (RXII) To Present New Data In Its First Phase 2a Clinical Trial With RXI-109 10/7/2014
StemCells Inc. (STEM) Initiates Phase 2 Clinical Trial In Cervical Spinal Cord Injury 10/7/2014
Biocryst Pharmaceuticals (BCRX) Announces Late Breaker Presentation Of Opus-1 Phase 2 Trial Results At The 23rd EADV Congress 10/7/2014
OXiGENE (OXGN) Announces Presentation Of Data From The Phase 2 GOG186I Study At The 15th Biennial Meeting Of The International Gynecologic Cancer Society 10/7/2014
Phosphagenics Limited (POH.AX) Announces Successful Results From Its Phase 2 TPM®/Tretinoin Gel Study On Acne Patients 10/7/2014
Galderma Initiates U.S. Study Of Novel Muscle Relaxant For Aesthetic Dermatology And Cosmetic Surgery 10/6/2014
Scioderm, Inc. To Present Data From Phase 2b Study Of Zorblisa™ (SD-101) At The 13th Annual Scioderm Investor Forum 10/6/2014
Horizon Pharma plc.  (HZNP) Receives Orphan-Drug Designation For ACTIMMUNE(R) (Interferon gamma-1b) In Friedreich's Ataxia 10/6/2014
Highland Therapeutics To Present Phase 2 Data On HLD-100, HLD-200 At AACAP Annual Meeting 10/6/2014
BrainStorm Cell Therapeutics Inc. Reports Last Patient Visit In Phase 2a ALS Study 10/6/2014
Collaboration With Dr. Stephen Waxman Of Yale University To Evaluate Pharmacology Of Nav1.7 Mutations In Chronic Pain Disorders 10/6/2014
Data From Alder Biopharmaceuticals Inc.' Proof-Of-Concept Clinical Trial Of ALD403 Published In Lancet Neurology Demonstrates ALD403 Effective In The Preventive Treatment Of Migraine 10/6/2014
Capricor Therapeutics, Inc. Announces Plans To Pursue Clinical Program For The Treatment Of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs) 10/6/2014
Foamix Pharmaceuticals, Ltd. (FOMX) Announces Initiation Of Phase 2 Trial With FDX104 In Chemotherapy Induced Rash 10/6/2014
Halozyme Therapeutics, Inc. (HALO) Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer 10/3/2014
Receptos (RCPT) Announces First Patient Treated With Anti-Interleukin-13 Antibody In Phase 2 Trial For Eosinophilic Esophagitis 10/3/2014
Esperion Therapeutics, Inc. (ESPR)'s ETC-1002-008 Succeeds In Lowering LDL Cholesterol 10/2/2014
Eleven Biotherapeutics (EBIO)' EBI-005 Misses Primary Endpoint In Phase 2 Trial 10/2/2014
Isis Pharmaceuticals, Inc. (ISIS) To Host Webcast To Discuss ISIS-SMN Rx Results Presented At The World Muscle Society Congress 10/2/2014
Amgen (AMGN) Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy Of Dermatology And Venereology 10/2/2014
Ardelyx Inc. (ARDX) Irritable Bowel Syndrome Drug Succeeds In Phase 2b Trial 10/1/2014
AbbVie (ABBV) Demonstrates Commitment To Continued Research In Hepatitis C With Investigational Data From Clinical Program Being Presented At The Liver Meeting® 10/1/2014
Rebiotix Release: Results of Study Assessing Microbiota-Based Drug Targeted At Recurrent C. difficile Infection To Be Presented At ACG 2014 10/1/2014
Tobira Therapeutics Inc.' Cenicriviroc Shows Improvement In Liver Fibrosis Scores In Phase 2b Study To Be Presented At AASLD 10/1/2014
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN)'s Dupilumab Successful In Phase 2 Study 9/30/2014
CytRx Corporation (CYTR) Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer 9/30/2014
Merrimack Pharmaceuticals Inc. (MACK) Presents Additional Phase 2 Biomarker Data Further Strengthening The Finding That MM-121 Increases Progression Free Survival In Patients With Biomarker Positive Metastatic Breast Cancer 9/30/2014
Array BioPharma, Inc. (ARRY) Release: Phase 2 Trial Of Binimetinib In NRAS Melanoma Shows Promising Clinical Activity 9/29/2014
TONIX Pharmaceuticals, Inc. (TNXP)'s Pain Drug Fails Phase 2b Study 9/29/2014
Clovis Oncology (CLVS) Release: Data From Ongoing Phase 2 Studies Of Rucaparib In Ovarian Cancer Demonstrate Safety And Clinical Activity, Validate Differentiated Strategy 9/29/2014
Amarantus BioSciences, Inc. Requests Pre-IND Feedback From FDA For Eltoprazine Phase 2ib Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial 9/29/2014
AVEO Oncology (AVEO) And Biodesix, Inc. Announce Exploratory Analysis Of Veristrat-Selected Patients With Non-Small Cell Lung Cancer In Phase 2 Study Of Ficlatuzumab Presented At ESMO 2014 Congress 9/29/2014
Ipsen (IPN.PA) Presents Preliminary Results Of Exploratory Proof-Of-Concept Study With Tasquinimod In Four Advanced Tumor Types At The ESMO 2014 Congress 9/29/2014
Biothera To Present Late-Breaking Data From Its Phase 2 9/29/2014
Puma Biotechnology (PBYI) Announces Positive Initial Results From PB272 Phase II Trial In HER2 Mutated Non-Small Cell Lung Cancer 9/29/2014
AVEO Oncology (AVEO) Announces Results From Phase 2 Clinical Studies Of Tivozanib In Patients With Advanced Colorectal And Kidney Cancers Presented At ESMO 2014 Congress 9/29/2014
Karyopharm Therapeutics (KPTI) Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors 9/29/2014
TRANSGENE (ENX:TNG) Presents Additional Positive Clinical Data From Phase 2b Part Of TIME Trial With TG4010 At ESMO 9/29/2014
OncoMed Pharmaceuticals, Inc. (OMED) Presents Encouraging Data From Clinical Trials Of Tarextumab (Anti-Notch2/3) In Pancreatic Cancer And Small Cell Lung Cancer At The ESMO 2014 Congress 9/29/2014
Viralytics Ltd (VLA.AX) Release: Updated Positive Data From Phase 2 Trial Of CAVATAK In Late-Stage Melanoma 9/29/2014
Acasti Pharmai Reports Successful Capre® Phase 2 TRIFECTA Results Proving Statistically Significant Improvements In Triglycerides & Non-HDL-C 9/29/2014
Bionomics Limited (BNO.AX) Presents BNC105 Phase 2 Renal Cancer Trial Biomarker Data 9/29/2014
CytRx Corporation (CYTR) Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer 9/29/2014
AbbVie (ABBV) Presents Results From Multiple Studies Of Investigational Compound Veliparib In Patients With Non-Small Cell Lung Cancer At The European Society For Medical Oncology Annual Congress 9/29/2014
Endocyte, Inc. (ECYT) Release: Phase 2b TARGET Trial Results Show Improved Survival In Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated With Endocyte's Vintafolide 9/29/2014
European CHMP Adopts Positive Opinion For Gilead Sciences, Inc. (GILD)’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment Of Chronic Hepatitis C Infection In Adults 9/26/2014
Proton Treatment Study At Loma Linda University Medical Center Reveals Excellent Breast Cancer Survival Rates And Cosmetic Outcomes 9/26/2014
Akebia Therapeutics, Inc. (AKBA) Announces Dosing Of First Patient In Phase 2 Study Of AKB-6548 In Patients With Anemia Related To Chronic Kidney Disease Undergoing Dialysis 9/25/2014
Celldex Therapeutics, Inc. (CLDX) Initiates Pilot Study Of CDX-301 In Allogeneic Hematopoietic Stem Cell Transplantation 9/25/2014
Meritage Pharma Announces Positive Results Of Oral Budesonide Suspension For Treatment Of Eosinophilic Esophagitis In Adolescent And Adult Patients 9/25/2014
Zafgen (ZFGN) Completes Enrollment Of Phase 2a Trial Of Beloranib In Hypothalamic Injury-Associated Obesity 9/25/2014
MabVax Therapeutics, Inc. Receives Orphan Drug Designation For Therapeutic Vaccine To Treat Childhood Cancer Neuroblastoma 9/25/2014
MediciNova, Inc. Provides Update On Phase 2b Trial Of MN-166 (Ibudilast) In Progressive MS 9/24/2014
Galmed Pharmaceuticals Announces U.S. FDA Approval Of Fast Track Designation Of Aramchol For The Treatment Of NASH 9/23/2014
Invion Limited Provides Update To U.S. FDA On Phase II Study Of Nadolol In Mild Asthma (NIMA) 9/23/2014
NOXXON Pharma AG Spiegelmer® Receives FDA Orphan Drug 9/23/2014
Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof Of Concept In Second Neuropathic Pain Study In Lumbosacral Radiculopathy 9/23/2014
Gilead Sciences, Inc. (GILD)'s Experimental Drug Simtuzumab Fails Mid-Stage Study 9/22/2014
BioBlast Pharma (ORPN) Announces Initiation Of Its Canadian OPMD Clinical Study Center At McGill University, Montreal 9/22/2014
DBV Technologies Announces Primary Endpoint Met In VIPES, Viaskin Peanut's Phase 2b Clinical Trial In Peanut Allergy 9/22/2014
FibroGen, Inc.Announces One-Year Data Supporting The Safety And Efficacy Profile Of FG-3019 In Patients With Idiopathic Pulmonary Fibrosis 9/22/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1102 For MS – Phase II Trial Results Published In The Leading Medical Journal Neurology 9/22/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1102 For MS - Phase II Trial Results Published In The Leading Medical Journal Neurology 9/22/2014
Progenics Pharmaceuticals, Inc. (PGNX) Presents Long Term Follow-Up Of Pivotal Phase 2 Trial Of Azedra In Malignant Pheochromocytoma 9/22/2014
AbbVie (ABBV) To Present Clinical Study Data On Potential New Oncology Medicines At The 2014 European Society Of Medical Oncology Annual Meeting 9/22/2014
Flexion Therapeutics (FLXN) Reports FDA Clinical Hold For Phase 2b Trial Of Osteoarthritis Drug 9/19/2014
Alexion Pharmaceuticals Inc. (ALXN) Release: Paediatric Patients With Hypophosphatasia Receiving Investigational Asfotase Alfa Had Sustained Improvements In Growth And Physical Function 9/19/2014
Umecrine Mood Announces Positive Results From An Exploratory Phase I/II Study With UC1010 In Premenstrual Dysphoric Disorder (PMDD) 9/19/2014
Galapagos NV (GLPG.BR) Reports High Participation Rate In Long Term Extension Study With GLPG0634 In RA Patients 9/18/2014
SWOG To Resume Clinical Trial Of Halozyme Therapeutics, Inc. (HALO)'s PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 9/18/2014
Auxilium Pharmaceuticals (AUXL) Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 9/18/2014
Immune Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial In Ulcerative Colitis 9/18/2014
Rebiotix Release: PUNCH CD Study Drug Targeting Recurrent C. Difficile Infection To Be Presented At IDWeek 2014 9/18/2014
ProSensa Holding N.V. (RNA) Announces Commencement Of Re-Dosing Of Drisapersen In North America In Patients With Duchenne Muscular Dystrophy 9/18/2014
Heat Biologics Commences Patient Dosing In Phase 2 Study Of Viagenpumatucel-L For The Treatment Of Non-Small Cell Lung Cancer 9/18/2014
OXiGENE (OXGN) Initiates Phase 2 Study Of Fosbretabulin In Gastrointestinal Neuroendocrine Tumors 9/18/2014
Oncolytics Biotech Inc. (ONC.TO) Announces Overall And KRAS-Mutated Patient Data From U.S. Randomized Phase 2 Pancreatic Cancer Study 9/17/2014
Amarantus BioSciences, Inc. Provides Program Update On Phase 2b Eltoprazine For Parkinson's Disease And Adult ADHD 9/17/2014
Moberg Pharma AB (Formerly known as Moberg Derma) Announces Successful Results For MOB-015 In A Phase II Study For The Treatment Of Onychomycosis 9/17/2014
Glenmark Pharmaceuticals's TRPA1 Antagonist 'GRC 17536' Shows Positive Data In A Proof Of Concept Study 9/17/2014
Neuraltus Pharmaceuticals, Inc.' ALS Treatment Candidate, NP001, Highlighted At ALS Research Group Summit 9/17/2014
Can-Fite BioPharma (CFBI)'s Drug CF101 Is Presented In Scientific Journal As One Of Four Small Molecule Drugs For The Treatment Of Psoriasis 9/17/2014
BioBlast Pharma (ORPN) Announces Preclinical And Clinical Pharmacokinetic Results With Cabaletta, Interim Safety Results From Phase 2/3 HOPEMD Study In OPMD 9/17/2014
Novavax, Inc. (NVAX) Initiates Phase 2 Clinical Trial Of RSV F-Protein Nanoparticle Vaccine Candidate In Healthy Third-Trimester Pregnant Women 9/17/2014
AVANIR Pharmaceuticals (AVNR) Rockets As Lead Drug Succeeds In Reducing Alzheimer's Related Agitation; Stock Up 63.20% At 10:19AM ET On Monday 9/16/2014
Cardioxyl Pharmaceuticals Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 9/16/2014
Anergis Reports Positive Long-Term Clinical Efficacy Of Lead Compound AllerT 9/16/2014
Coldstream Laboratories Inc. Partners With CytImmune Sciences Inc. For Phase 2 Sterile Manufacturing 9/16/2014
Ascendis Pharma A/S Announces Positive Interim Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone For The Treatment Of Growth Hormone Deficiency 9/16/2014
NovaBiotics Ltd Receives Orphan Drug Status From FDA For Lynovex® For The Treatment Of Cystic Fibrosis 9/16/2014
Ophthotech Corporation (OPHT) Announces Fovista® Phase 2b Independent Analysis Shows That Fovista® Anti-PDGF Therapy, Combined With Anti-VEGF Therapy, Is Associated With A Reduction Of Sub-Retinal Fibrosis In Wet AMD Patients 9/16/2014



//-->